FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

Although programmed death-ligand 1 (PD-L1) antibody-based therapy has improved the outcome of patients with cancer, acquired resistance to these treatments limits their clinical efficacy. FS118 is a novel bispecific, tetravalent antibody (mAb ) against human lymphocyte activation gene-3 (LAG-3) and...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2020-07, Vol.26 (13), p.3333-3344
Hauptverfasser:	Kraman, Matthew, Faroudi, Mustapha, Allen, Natalie L, Kmiecik, Katarzyna, Gliddon, Daniel, Seal, Claire, Koers, Alexander, Wydro, Mateusz M, Batey, Sarah, Winnewisser, Julia, Young, Lesley, Tuna, Mihriban, Doody, Jacqueline, Morrow, Michelle, Brewis, Neil
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!